Does ADALIMUMAB Cause Hepatocellular carcinoma? 78 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 78 reports of Hepatocellular carcinoma have been filed in association with ADALIMUMAB (YUSIMRY). This represents 0.0% of all adverse event reports for ADALIMUMAB.
78
Reports of Hepatocellular carcinoma with ADALIMUMAB
0.0%
of all ADALIMUMAB reports
15
Deaths
42
Hospitalizations
How Dangerous Is Hepatocellular carcinoma From ADALIMUMAB?
Of the 78 reports, 15 (19.2%) resulted in death, 42 (53.8%) required hospitalization, and 10 (12.8%) were considered life-threatening.
Is Hepatocellular carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ADALIMUMAB. However, 78 reports have been filed with the FAERS database.
What Other Side Effects Does ADALIMUMAB Cause?
Drug ineffective (71,926)
Pain (37,514)
Arthralgia (35,592)
Rheumatoid arthritis (29,817)
Fatigue (29,420)
Injection site pain (28,679)
Headache (19,891)
Nausea (19,299)
Rash (18,690)
Pain in extremity (18,319)
What Other Drugs Cause Hepatocellular carcinoma?
SORAFENIB (1,665)
RIBAVIRIN (1,046)
SOFOSBUVIR (877)
LEDIPASVIR\SOFOSBUVIR (640)
BEVACIZUMAB (532)
REGORAFENIB (470)
DACLATASVIR (419)
ATEZOLIZUMAB (342)
CABOZANTINIB S-MALATE (219)
TACROLIMUS (183)
Which ADALIMUMAB Alternatives Have Lower Hepatocellular carcinoma Risk?
ADALIMUMAB vs ADALIMUMAB-AACF
ADALIMUMAB vs ADALIMUMAB-AATY
ADALIMUMAB vs ADALIMUMAB-ADAZ
ADALIMUMAB vs ADALIMUMAB-ADBM
ADALIMUMAB vs ADALIMUMAB-AFZB